Literature DB >> 8751247

Second primary lung cancer and relapse: treatment and follow-up.

C A Angeletti1, A Mussi, A Janni, M Lucchi, A Ribechini, A Chella, G Fontanini.   

Abstract

During a 14-year period (1980-1993) second primary lung cancer or relapse was treated in 44 consecutive patients. Thirty-seven patients had synchronous (n = 18) or metachronous (n = 19) second primary lung cancer. Ten synchronous tumors were ipsilateral and treated contemporarily with five pneumonectomies, three lobectomies and two double wedge resections. The bilateral synchronous lesions (8 patients) were treated by staged bilateral thoracotomy (mean interval; 2 months). The first resection consisted of a lobectomy in six patients and wedge resection in two. The second one was a wedge resection in six patients and a lobectomy in two. In the metachronous presentation 15 patients (79%) were asymptomatic and detected by follow-up chest X-ray. In this group the first operation was a lobectomy in 12 patients, a wedge resection or segmentectomy in 6 and a pneumonectomy in 1. The second one was a wedge resection in nine patients, a lobectomy in six and completion pneumonectomy in four. Seven patients, all of them asymptomatic, had local recurrence from their primary lung cancer. The first lung resection was a lobectomy in five patients and a wedge resection in two. The second one was completion pneumonectomy in five patients and completion lobectomy in two. We had no operative death. The actuarial over-all 5-year survival rate after the second pulmonary resection for second primary lung cancer was 38.3% with a median survival time of 13.5 months. The synchronous presentation had a better survival than the metachronous one (46.2% and 25.9%), respectively). The actuarial overall 5-year survival rate for patients with relapse was 38.1% with a median survival time of 37 months. We may conclude that an aggressive surgical approach is safe, effective and warranted in patients with either a second primary lung cancer or relapse from their primary lung cancer. Moreover, for early detection of the second lesions, follow-up at a maximum of 6-monthly intervals should be continued for more than 5 years after the first resection.

Entities:  

Mesh:

Year:  1995        PMID: 8751247     DOI: 10.1016/s1010-7940(05)80104-6

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  Clinical features of multiple lung cancers based on thin-section computed tomography: what are the appropriate surgical strategies for second lung cancers?

Authors:  Aritoshi Hattori; Kenji Suzuki; Kazuya Takamochi; Shiaki Oh
Journal:  Surg Today       Date:  2014-05-22       Impact factor: 2.549

2.  Surgical resection of recurrent lung cancer in patients following curative resection.

Authors:  Hyoung Soo Kim; Hoseok I; Yong Soo Choi; Kwhanmien Kim; Young Mog Shim; Jhingook Kim
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153

3.  Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population.

Authors:  Christopher T Erb; Kevin W Su; Pamela R Soulos; Lynn T Tanoue; Cary P Gross
Journal:  Lung Cancer       Date:  2016-07-19       Impact factor: 5.705

4.  Predictors of imaging surveillance for surgically treated early-stage lung cancer.

Authors:  Leah M Backhus; Farhood Farjah; Steven B Zeliadt; Thomas K Varghese; Aaron Cheng; Larry Kessler; David H Au; David R Flum
Journal:  Ann Thorac Surg       Date:  2014-10-03       Impact factor: 4.330

5.  Characteristics and prognosis of synchronous multiple primary lung cancer after surgical treatment: A systematic review and meta-analysis of current evidence.

Authors:  Hongtao Tie; Jun Luo; Rui Shi; Zhenhan Li; Dan Chen; Qingchen Wu
Journal:  Cancer Med       Date:  2020-12-10       Impact factor: 4.452

6.  Exhaled Breath Temperature Home Monitoring to Detect NSCLC Relapse: Results from a Pilot Study.

Authors:  Giovanna Elisiana Carpagnano; Todor A Popov; Giulia Scioscia; Nicoletta Pia Ardò; Donato Lacedonia; Mario Malerba; Pasquale Tondo; Piera Soccio; Domenico Loizzi; Maria Pia Foschino Barbaro; Francesco Sollitto
Journal:  Biomed Res Int       Date:  2022-02-21       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.